Reviewing Ginkgo Bioworks (NYSE:DNA) & Eternity Healthcare (OTCMKTS:ETAH)

Eternity Healthcare (OTCMKTS:ETAH) and Ginkgo Bioworks (NYSE:DNA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Eternity Healthcare and Ginkgo Bioworks”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eternity Healthcare	N/A	N/A	N/A	N/A	N/A
Ginkgo Bioworks	$170.15 million	2.88	-$312.76 million	($5.01)	-1.45

Eternity Healthcare has higher earnings, but lower revenue than Ginkgo Bioworks.

Analyst Recommendations

This is a summary of current recommendations for Eternity Healthcare and Ginkgo Bioworks, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eternity Healthcare	0	0	0	0	0.00
Ginkgo Bioworks	2	2	0	0	1.50

Ginkgo Bioworks has a consensus price target of $7.00, indicating a potential downside of 3.91%. Given Eternity Healthcare’s higher probable upside, equities research analysts clearly believe Eternity Healthcare is more favorable than Ginkgo Bioworks.

Insider & Institutional Ownership

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Eternity Healthcare and Ginkgo Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eternity Healthcare	N/A	N/A	N/A
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

About Eternity Healthcare

Eternity Healthcare, Inc. engages in the provision of stem cell storage and related medical therapies in China. Its services include cell derivation and cell banking. The company was founded on October 24, 2007 and is headquartered in Hong Kong.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.